Phase I/2 Placebo-Controlled, Randomized, Double-Blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 3 Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years.

Trial Profile

Phase I/2 Placebo-Controlled, Randomized, Double-Blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 3 Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 25 Apr 2017

At a glance

  • Drugs Staphylococcus aureus vaccine (Primary)
  • Indications Staphylococcal infections
  • Focus Adverse reactions; First in man; Pharmacodynamics
  • Sponsors Pfizer
  • Most Recent Events

    • 25 Apr 2017 Results (n=440) of this and one other study presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases.
    • 01 Dec 2016 Results published in the Vaccine.
    • 30 Oct 2016 Results of this and other study presented at the IDWeek 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top